CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BUTABARBITA ASSAY/		*USP38–NF33*	2500	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second*	Line 17 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
L SODIUM ORAL SOLUTION	*Procedure*						*Supplement to USP38–NF33*	*Analysis*: Change C_U = nominal concentration of butabarbital sodium in the *Sample solution* (µg/mL) to: C_U = nominal concentration of butabarbital sodium in the *Sample solution* (mg/mL)
CITRIC ACID, MAGNESIUM OXIDE, AND SODIUM CARBONATE IRRIGATION	ASSAY/*Citric Acid*	*USP38–NF33*	2844	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 16 of *Analysis*: Change C_U = nominal concentration of citric acid monohydrate in the *Assay preparation for citric acid/citrate assay* (units/mL) to: C_U = nominal concentration of citric acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								monohydrate in the *Assay preparation for citric acid/citrate assay* (µg/mL)
AZITHROMYCIN	IMPURITIES/*Organic Impurities/Procedure 1*	*USP37–NF32*	1886	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 6 of *Analysis*: Change Calculate the percentages of desosaminylazithromycin and *N* -demethylazithromycin in the portion of Azithromycin taken: to: Calculate the percentages of desosaminylazithromycin, *N* -demethylazithromycin, and azaerythromycin A in the portion of Azithromycin taken:
VALSARTAN AND HYDROC	ADDITIONAL REQUIREMENT	*Revision Bulletin (Official*	Online	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to*	Line 2 of USP Valsartan

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HLOROTHIAZIDE TABLETS	S/*USP Reference Standards <11>*	*April 01, 2014)*					*USP38–NF33*	Related Compound B RS: Change (*S*-*N* -Butyryl -*N* -([2?-(1*H* -tetrazole-5-yl)biphen-4-yl]methyl)-valine. to: *N* -Butyryl -*N* -{[2?-(1*H* -tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine.
HYDROGEN PEROXIDE CONCENTRATE	ASSAY/ *Procedure*	*USP37–NF32*	3272	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Sample solution*: Change 1 mL of Concentrate, diluted to 100 mL to: Weigh about 1 mL of Concentrate in a 100-mL

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volumetric flask, and dilute with water to volume.
POTASSIUM BITARTRATE	IDENTIFICATION	*USP37–NF32*	4346	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Change *C. Identification Tests—General, Tartrate <191>* to: *C. Identification Tests—General, Tartrate <191>*: Meets the requirements AND Delete subsections: *Sample solution*: 1 in 10 solution *Acceptance criteria*: Meets the requirements
ZIPRASIDONE HYDROCHLORIDE	IMPURITIES/*Limit of Tetrahydrofuran*	*USP37–NF32*	5219	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Standard solution*: Change 0.05 mg/mL of USP Ziprasidone

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Hydrochloride RS in dimethyl sulfoxide to: 0.05 mg/mL of tetrahydrofuran in dimethyl sulfoxide
AMIODARONE HYDROCHLORIDE	ORGANIC IMPURITIES/ *Procedure 1*/ *Chromatographic system*	*USP38–NF33*	2198	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Adsorbent*: Change 0.5-mm layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm to: Suitable layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm
CAFFEINE CITRATE ORAL	ASSAY/ *Procedure*	*USP38–NF33*	2521	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 5 of *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SOLUTION								Result = (r_U/r_S) × C_S × (M_{r1}/M_{r2}) × 100 to: Result = (r_U/r_S) × C_S × (M_{r1}/M_{r2})
PAROXETINE HYDROCHLORIDE	IM PURITIES/*Limit of 1-Methyl-4-(p-fluorophenyl)-1,2,3,6-tetrahydropyridine*	*USP38–NF33*	4765	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Standard solution*: Change 42 mg/mL to: 42 ng/mL
ESTRADIOL VAGINAL INSERTS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP37–NF32*	2866	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 3 of *Analysis*: Change Calculate the amount of estradiol ($C_{18}H_{24}O_2$) dissolved: to: Record the chromatograms, and measure the responses for the estradiol peak. Construct a calibration curve by plotting the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								peak response versus concentration of the *Standard solutions*. Determine the amount of estradiol ($C_{18}H_{24}O_2$) in the *Sample solutions* from a linear regression analysis of the calibration curve. Calculate the amount of estradiol ($C_{18}H_{24}O_2$) dissolved:
CIPROFLOXACIN EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official October 01, 2014)*	Online	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 16 of *Analysis*: Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to: *M*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								M_{r2}= molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81 AND Line 14 of the second Calculate statement in *Analysis*: Change M_{r2} = molecular weight of ciprofloxacin hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
PACLITAXEL	*Related compounds/Test 2 (for Material Labeled as Produced by a*	*USP37–NF32*	4163	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 6 after table in *Chromatographic system*: Change the relative

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Semisynthetic Process)							standard deviation for replicate injections is not more than 2.0%. to: the relative standard deviation for replicate injections is not more than 2.0% for the paclitaxel peak.
TETRACAINE OINTMENT	*Assay*	*USP37–NF32*	4891	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 7 of *Procedure*: Change (264.37/300.83)(*C*)(A_U / A_S) to: (264.36/300.82)(*C*)(A_U / A_S)
GLYCERYL BEHENATE	ASSAY/ *Procedure/ Chromatographic system*	*Second Supplement to USP37–NF32*	7075	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Column*: Change 7.0-mm × 60-cm; 5-µm packing L21 [Note—Two 7.0-mm ×

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								30-cm L21 columns to: 7.5-mm × 60-cm; 5-µm 100-Å packing L21 [Note—Two 7.5-mm × 30-cm L21 columns
BUTABARBITAL SODIUM TABLETS	PERFORMANCE TESTS/ *Uniformity of Dosage Units <905>/Procedure for content uniformity*	*USP38–NF33*	2501	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 18 of *Analysis*: Change C_U = nominal concentration of butabarbital sodium in the *Sample solution* to: C_U = nominal concentration of butabarbital sodium in the *Sample solution* (mg/mL)
ESCITALOPRAM TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP38–NF33*	3364	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 13 of *Analysis*: Change M_{r2} = molecular weight of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								escitalopram oxalate, 405.30 to: M_{r2} = molecular weight of escitalopram oxalate, 414.43
AZITHROMYCIN	SPECIFIC TESTS/*pH <791>*	*USP37–NF32*	1886	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Sample solution*: Change 2 mg/mL from the *Sample stock solution* in a mixture of methanol and water (1:1) to: 2 mg/mL obtained by mixing equal volumes of *Sample stock solution* and water
CIPROFLOXACIN EXTENDED-RELEASE TABLETS	ASSAY/ *Procedure*	*Revision Bulletin (Official October 01, 2014)*	Online	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 17 of *Analysis*: Change M_{r2} = molecular weight of ciprofloxacin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride, 367.81 to: M_{r2} = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
HYOSCYAMINE SULFATE	*USP Reference standards <11>*	*USP37–NF32*	3293	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 2 of USP Hyoscyamine Related Compound A RS: Change (1*R*,3*R*,5*S*)-8-azabicyclo[3.2.1]oct-3-yl(2*S*)-3-hydroxy-2-phenylpropanoate. to: (1*R*,3*r*,5*S*)-8-Azabicyclo[3.2.1]oct-3-yl(2*S*)-3-hydroxy-2-phenylpropanoat

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								e sulfate (2:1).
POTASSIUM SODIUM TARTRATE	*Identification/C:*	*USP37–NF32*	4369	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Change A solution (1 in 10) responds to the tests for *Tartrate <191>*. to: Responds to the tests for *Tartrate <191>*.
RED CLOVER TABLETS	SPECIFIC TESTS/ *Microbial Enumeration Tests <2021>*	*USP37–NF32*	5526	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 4: Change NLT 10^3 cfu/g. to: NMT 10^3 cfu/g.
ATROPINE SULFATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	2325	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 2 of USP Hyoscyamine Related Compound A RS: Change Norhyoscyamine sulfate; (1*R*,3*r*,5*S*)-8-azabicyclo[3.2.1]oct-3-yl(2*S*)-3-hydroxy-2-phenylpropanoat

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								e.$C_{16}H_{21}NO_3$ 275.34 to: Norhyoscyamine sulfate; (1*R*,3*r*,5*S*)-8-Azabicyclo[3.2.1]octan-3-yl (*S*)-3-hydroxy-2-phenylpropanoate sulfate (2:1).($C_{16}H_{21}NO_3)_2 \cdot H_2SO_4$ 648.77
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE TABLETS	ASSAY/ *Procedure*	*USP38–NF33*	2752	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Buffer*: Change 0.20 sodium hydroxide to: 0.20 N sodium hydroxide
PAROXETINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	4765	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Lines 4 and 7 of USP Paroxetine System Suitability Mixture A RS: Change hydrochloride (3 *S-trans*) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride (3*S-trans*)
GADOVERSETAMIDE INJECTION	*Relaxivity <761>*	*USP37–NF32*	3121	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Apparatus*: Change Use a mini-NMR spectrometer with suitable sensitivity (see *Apparatus* under *Nuclear Magnetic Resonance <761>*). to: Use an NMR spectrometer with suitable sensitivity.
BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official October 01, 2014)*	Online	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Row 4 of Column 1 of *Table 16*: Change *R*,*S*,*S*,-Thiomorpholine derivative[c] to: *S*,*R*,*R*,-Thiomorpholine derivative[c]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PANCURONIUM BROMIDE	ASSAY/ *Procedure/ Chromatographic system*	*USP37–NF32*	4176	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Column*: Change 4.6-mm × 250-cm; 5-µm packing L1 to: 4.6-mm × 25-cm; 5-µm packing L1
VALSARTAN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP37–NF32*	5116	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Medium*: Change pH 6.8 phosphate buffer; 1000 mL, degassed to: pH 6.8 phosphate buffer prepared as follows. Dissolve 6.805 g of monobasic potassium phosphate and 0.896 g of sodium hydroxide in and dilute with water to 1000

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mL. Adjust with 0.2 M sodium hydroxide or 1 M phosphoric acid as required to a pH of 6.8; 1000 mL degassed.
RISPERIDONE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP37–NF32*	7240	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 2 of USP Risperidone Related Compound G RS: Change 3-[2-[4-(4-Fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one. $C_{23}H_{28}FN_3O_3$ 413.49 to: 3-[2-[4-(4-Fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetra

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydro-4*H*-pyri do[1,2-*a*]pyrimidin-4-one hydrochloride. $C_{23}H_{28}FN_3O_3 \cdot HCl$ 448.94
CAFFEINE CITRATE INJECTION	ASSAY/ *Procedure*	*USP38–NF33*	2520	30-Jan-2015	1-Feb-2015	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 5 of *Analysis*: Change Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(r_U/r_S) \times C_S \times (M_{r1}/M_{r2})$
CEFUROXIME AXETIL FOR ORAL SUSPENSION	ASSAY/ *Procedure*	*USP37–NF32*	2243	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Change *Buffer*: 23 mg/mL of monobasic ammonium phosphate in water to: *Solution A*: 23 g/L of monobasic ammonium phosphate in water AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 4 of *System suitability solution*: Change Dilute with *Buffer* to volume. to: Dilute with *Solution A* to volume. AND Line 3 of *Standard solution*: Change and dilute with *Buffer* to volume. to: and dilute with *Solution A* to volume. AND Line 3 of *Sample solution*: Change and dilute with *Buffer* to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volume. to: and dilute with *Solution A* to volume.
GANODERMA LUCIDUM FRUITING BODY POWDER	COMPOSITION /*Content of Triterpenoic Acids*	*Revision Bulletin (Official August 01, 2014)*	Online	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Standard solution A*: Change USP Ganoderic Acid RS to: USP Ganoderic Acid A RS AND Line 3 of variable definition list in *Analysis*: Change r_S = peak area of ganoderic acid in *Standard solution A* to: r_S = peak area of ganoderic acid A in *Standard solution A* AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MANNITOL INJECTION	*Assay*	*USP37–NF32*	3653	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 11 of variable definition list in *Analysis*: Change *F* = relative response factor, with respect to ganoderic acid A (see *Table 3*) to: *F* = relative response factor, with respect to ganoderic acid A (see *Table 2*) Change: *Mobile phase*, *Resolution solution*, and *Chromatographic system* —Proceed as directed in the *Assay* under *Mannitol*. to: *Mobile phase*—Use degassed

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								water. *Resolution solution* —Dissolve sorbitol and USP Mannitol RS in water to obtain a solution having concentrations of about 4.8 mg per mL of each. *Chromatographic system* (see *Chromatography <621>*)—The liquid chromatograph is equipped with a refractive index detector that is maintained at a constant temperature and a 4-mm × 25-cm column that contains packing L19. The column temperature is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								maintained at a temperature between 30° and 85° controlled within ±2° of the selected temperature, and the flow rate is about 0.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the relative standard deviation for replicate injections is not more than 2.0%. In a similar manner, chromatograph the *Resolution solution*: the resolution, *R*, between the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sorbitol and mannitol peaks is not less than 2.0. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under Mannitol. to: Separately inject equal volumes (about 20 µL) of the *Assay preparation* and the *Standard preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
SACCHARIN	IDENTIFICATIO	*USP37–NF32*	4638	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM	N/*B. Procedure*						*Supplement to USP38–NF33*	*Analysis*: Change To the *Sample solution* to: To 10 mL of the *Sample solution*
ZANAMIVIR	ASSAY/*Procedure/Chromatographic system*	*USP37–NF32*	5197	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Column*: Change 5-?m packing L##[1] to: 5-?m packing L82 AND Delete footnote 1
COPOVIDONE	IM PURITIES/*Limit of Monomers (1-Vinyl-2-Pyrrolidone, Vinyl Acetate, and 2-Pyrrolidone)*	*USP37–NF32*	5938	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 29 of *Analysis*: Change Calculate the content of 2-pyrrolidinone to: Calculate the content of 2-pyrrolidone
GLYCERYL BEHENATE	DEFINITION	*Second Supplement to*	7077	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to*	Line 7: Change behenic

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
		USP37–NF32					*USP38–NF33*	(docosanic) acid to: behenic (docosanoic) acid
METHODS FOR THE DETERMINATION OF PARTICULATE MATTER IN INJECTIONS AND OPHTHALMIC SOLUTIONS	LIGHT OBSCURATION PARTICLE COUNT TEST/ *Instrument Standardization Tests*/*Particle Counting Accuracy—System Suitability*	*USP37–NF32*	1301	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 11 of *Method 2—Multichannel Instruments*: Change NMT ±10% of stated size. to: NMT ±10% of stated concentration.
GANODERMA LUCIDUM FRUITING BODY	COMPOSITION /*Content of Triterpenoic Acids*	*Revision Bulletin (Official August 01, 2014)*	Online	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Standard solution A*: Change USP Ganoderic Acid RS to: USP Ganoderic Acid A RS AND Line 3 of variable definition list in *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change r_S = peak area of ganoderic acid in *Standard solution A* to: r_S = peak area of ganoderic acid A in *Standard solution A* AND Line 10 of variable definition list in *Analysis*: Change *F* = relative response factor, with respect to ganoderic acid A (see *Table 3*) to: *F* = relative response factor, with respect to ganoderic acid A (see *Table 2*)
FLUTAMIDE	ASSAY/ *Procedure*	*USP37–NF32*	3057	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 2 of *Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Dissolve the sample in acetonitrile to: Dissolve a previously dried sample in acetonitrile
PETROLATUM	IM PUR ITIES/*Organic Impuri ties*/*Procedure: Organic Acids*	*USP37–NF32*	4253	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 1 of *Sample solution*: Change 20.0 g of Petrolatum in 100 mL of neutralized alcohol and water (1:2). to: 20.0 g of Petrolatum in 100 mL of a 1 in 2 mixture of neutralized alcohol and water.
SULFAMETHO XAZOLE AND T RIMETHOPRIM ORAL	ASSAY/ *Procedure*	*USP37–NF32*	4785	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 3 of *Standard solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SUSPENSION								in *Mobile phase* from *Sample stock solution* to: in *Mobile phase* from *Standard stock solution*
TRIBASIC CALCIUM PHOSPHATE	ASSAY/ *Procedure*	*USP37–NF32*	5883	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Delete the subsection *Blank*: Proceed as directed in the *Analysis*, omitting the test specimen. AND Equation in *Analysis*: Change Result = {[V_S ? V_B) × M × F]/W} × 100 to: Result = [(V_S × M × F)/W] × 100 AND Line 2 of the variable definition list in *Analysis*: Delete *V*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_B$= *Titrant* volume consumed by the *Blank* (mL)
TRAZODONE HYDROCHLORIDE	IM PURITIES/*Limit of Trazodone Related Compound F and Cyclophosphamide Related Compound A/ Chromatographic system/MS conditions*	*First Supplement to USP37–NF32*	6708	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 4 of *Acquisition mode*:Change 272 to: 273
MEBENDAZOLE	ASSAY/ *Procedure*	*Second Supplement to USP37–NF32*	7199	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 3 of *Analysis*: Change Calculate the percentage of each impurity in the portion of Oral Suspension taken: to: Calculate the percentage of mebendazole ($C_{16}H_{13}N_3O_3$) in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the portion of Mebendazole taken:
DOLASETRON MESYLATE	CHEMICAL INFORMATION	*USP37–NF32*	2693	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 7: Change [115956-13-3]. to: [878143-33-0] Anhydrous [115956-13-3].
FENTANYL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP37–NF32*	Online	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Delete USP Fentanyl Related Compound C RS AND Delete USP Fentanyl Related Compound F RS
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/*Dissolution <711>*	*USP37–NF32*	3732	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Equation in *Test 1*: Change Result = $[(A_U/A_S) \times C_S \times (V ? V_S) + (C_{60} \times V_S) + (C_{180} \times V_S) \times 100]/L$ to: Result = $[(A_U/A_S) \times C_S \times (V ? V$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_S$) + (C_{60} ×V_S) + (C_{180} ×V_S)] ×(100/L) AND Equation 3 in *Test 2*: Change Result = [C_2 × (V ? SV_1) + C_1 ×SV_1 ×100]/L to: Result = [C_2 × (V ? SV_1) + C_1 ×SV_1] ×(100/L) AND Equation 4 in *Test 2*: Change Result = {C_n ×[V ? (n ? 1)V_S] + (C_1 + C_2 + ... + C_{n-1}) × V_S ×100}/L to: Result = {C_n ×[V ? (n ? 1)V_S] + (C_1 + C_2 + ... + C_{n-1}) × V_S} ×(100/L)
SACCHARIN SODIUM	IM PUR ITIES/*Organic Impuri*	*USP37–NF32*	4638	21-Nov-2014	1-Dec-2014	*USP39–NF34*	*Second Supplement to USP38–NF33*	Line 4 of *Acceptance criteria*: Change of the *Internal*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ties/Procedure 1: Limit of Tolue nesulfonamides							*standard solution* to: of the caffeine (internal standard)

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 26
- Page 27
- Page 28
- Page 29
- Page 30
- Page 31
- Page 32
- Page 33
- Page 34
- …
- Next page Next ›
- Last page Last »